Mutual of America Capital Management LLC Trims Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Mutual of America Capital Management LLC decreased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) by 12.0% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 41,033 shares of the specialty pharmaceutical company’s stock after selling 5,590 shares during the period. Mutual of America Capital Management LLC owned approximately 0.07% of Jazz Pharmaceuticals worth $5,311,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Massmutual Trust Co. FSB ADV grew its holdings in Jazz Pharmaceuticals by 65.6% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 202 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 80 shares during the last quarter. ST Germain D J Co. Inc. purchased a new stake in shares of Jazz Pharmaceuticals in the second quarter worth approximately $40,000. Spire Wealth Management lifted its stake in shares of Jazz Pharmaceuticals by 128.6% during the 3rd quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock worth $55,000 after acquiring an additional 238 shares during the last quarter. Quadrant Capital Group LLC boosted its holdings in Jazz Pharmaceuticals by 58.1% during the 2nd quarter. Quadrant Capital Group LLC now owns 555 shares of the specialty pharmaceutical company’s stock valued at $69,000 after acquiring an additional 204 shares during the period. Finally, Signaturefd LLC grew its position in Jazz Pharmaceuticals by 85.7% in the 3rd quarter. Signaturefd LLC now owns 546 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 252 shares during the last quarter. Institutional investors own 88.15% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $123.43 on Monday. The company has a market cap of $7.77 billion, a P/E ratio of 140.26, a price-to-earnings-growth ratio of 0.94 and a beta of 0.62. The company has a quick ratio of 1.67, a current ratio of 2.06 and a debt-to-equity ratio of 1.46. The firm’s 50-day moving average price is $122.07 and its 200-day moving average price is $127.82. Jazz Pharmaceuticals plc has a 52-week low of $111.25 and a 52-week high of $152.90.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on JAZZ shares. Barclays decreased their target price on Jazz Pharmaceuticals from $240.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, January 29th. Robert W. Baird assumed coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $160.00 price target for the company. UBS Group lowered Jazz Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the company from $170.00 to $135.00 in a report on Monday, November 27th. Truist Financial restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Monday, December 4th. Finally, Royal Bank of Canada lowered their target price on Jazz Pharmaceuticals from $200.00 to $191.00 and set an “outperform” rating for the company in a report on Thursday, November 9th. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $195.90.

View Our Latest Analysis on JAZZ

Insiders Place Their Bets

In other news, Director Mark Douglas Smith sold 417 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $119.27, for a total transaction of $49,735.59. Following the sale, the director now directly owns 6,888 shares of the company’s stock, valued at $821,531.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.40% of the stock is owned by insiders.

Jazz Pharmaceuticals Profile

(Free Report)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors.

Recommended Stories

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.